A recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13

Abstract

The pneumococcal conjugate vaccine (PCV) strongly protects against vaccine serotypes, but the rapid expansion of non-vaccine serotype disease and the vaccine’s high expense has reduced its overall impact. We have developed Protein Glycan Coupling Technology (PGCT) as a flexible methodology for making low-cost polysaccharide/protein glycoconjugates recombinantly in Escherichia coli. We have used PGCT to make a recombinant PCV containing serotype 4 capsular polysaccharide linked to the Streptococcus pneumoniae proteins NanA, PiuA, and Sp0148. The introduction of the Campylobacter jejuni UDP-glucose 4-epimerase gene GalE (gne) into E. coli improved the yield of the resulting glycoprotein. PGCT glycoconjugate vaccination generated strong antibody responses in mice to both the capsule and the carrier protein antigens, with the PiuA/capsule glycoconjugate inducing similar anti-capsular antibody responses as the commercial PCV Prevnar-13. Antibody responses to PGCT glycoconjugates opsonised S. pneumoniae and Streptococcus mitis expressing the serotype 4 capsule and promoted neutrophil phagocytosis of S. pneumoniae to a similar level as antisera generated by vaccination with Prevnar-13. Vaccination with the PGCT glycoconjugates protected mice against meningitis and septicaemia with the same efficacy as vaccination with Prevnar-13. In addition, vaccination with the protein antigen components from PGCT glycoconjugates alone provided partial protection against septicaemia and colonisation. These data demonstrate that a vaccine made by PGCT is as effective as Prevnar-13, identifies PiuA as a carrier protein for glycoconjugate vaccines, and demonstrates that linking capsular antigen to S. pneumoniae protein antigens has additional protective benefits that could provide a degree of serotype-independent immunity.

Can animal models really teach us anything about pneumonia? Pro

“…Identification of Th17 antigens that protect against S. pneumoniae [91] Confirmation that vaccination with a recombinant glycoconjugate is as efficacious as Prevnar vaccination against S. pneumoniae [92] Assessing efficacy of immunomodulation…”

Diagnostic approaches of pneumonia for commercial-scale biomedical applications: an overview

“…Pneumococcal conjugate antibody (otherwise called Prevnar) and pneumococcal polysaccharide vaccine (known as Pneumovax) are utilized for prevention of bacterial pneumonia (Ngari et al 2014;Andrews et al 2019). Prevnar (PCV13) is ordinarily included as a major aspect of a newborn child's normal vaccinations (Reglinski et al 2018). It is recommended for kids under 2 years, adults more than 65 years, and those between the ages of 2 and 64 years with certain ailments.…”

Application of an O-Linked Glycosylation System in Yersinia enterocolitica Serotype O:9 to Generate a New Candidate Vaccine against Brucella abortus

“…It has been demonstrated that an N-linked glycosyltransferase, PglB, from Campylobacter jejuni can be expressed in Escherichia coli and catalyze the glycosylation of its natural substrate, AcrA [28]. Subsequently, various vaccines based on the PglB glycosylation system were developed, including vaccines against Shigella dysenteriae type I [29], Francisella tularensis [30], Staphylococcus aureus [31], and Streptococcus pneumoniae [32,33]. Several of these vaccines have entered clinical trials [25].…”